Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group. Grønberg BH, et al. Among authors: brustugun ot. Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23. Acta Oncol. 2016. PMID: 26494411 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Primary osteosarcoma of the breast.
Brustugun OT, Reed W, Poulsen JP, Bruland OS. Brustugun OT, et al. Acta Oncol. 2005;44(7):767-70. doi: 10.1080/02841860500254897. Acta Oncol. 2005. PMID: 16227171 No abstract available.
[Mutation testing for non-small-cell lung cancer].
Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L. Brustugun OT, et al. Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. doi: 10.4045/tidsskr.11.1017. Tidsskr Nor Laegeforen. 2012. PMID: 22562326 Free article. Norwegian.
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Grønberg BH, Lund-Iversen M, Strøm EH, Brustugun OT, Scott H. Grønberg BH, et al. Among authors: brustugun ot. J Thorac Oncol. 2013 Oct;8(10):1255-64. doi: 10.1097/JTO.0b013e3182a406a3. J Thorac Oncol. 2013. PMID: 24457236 Free article. Clinical Trial.
151 results